JP2019518721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518721A5 JP2019518721A5 JP2018554645A JP2018554645A JP2019518721A5 JP 2019518721 A5 JP2019518721 A5 JP 2019518721A5 JP 2018554645 A JP2018554645 A JP 2018554645A JP 2018554645 A JP2018554645 A JP 2018554645A JP 2019518721 A5 JP2019518721 A5 JP 2019518721A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179905A JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276855P | 2016-01-09 | 2016-01-09 | |
| US62/276,855 | 2016-01-09 | ||
| PCT/US2017/012648 WO2017120557A1 (en) | 2016-01-09 | 2017-01-07 | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179905A Division JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518721A JP2019518721A (ja) | 2019-07-04 |
| JP2019518721A5 true JP2019518721A5 (https=) | 2020-02-20 |
| JP6974348B2 JP6974348B2 (ja) | 2021-12-01 |
Family
ID=59274048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554645A Active JP6974348B2 (ja) | 2016-01-09 | 2017-01-07 | がん処置のためのカドヘリン−１７特異的抗体及び細胞傷害性細胞 |
| JP2021179905A Active JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
| JP2023075948A Active JP7482287B2 (ja) | 2016-01-09 | 2023-05-02 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179905A Active JP7275232B2 (ja) | 2016-01-09 | 2021-11-04 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
| JP2023075948A Active JP7482287B2 (ja) | 2016-01-09 | 2023-05-02 | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11207419B2 (https=) |
| EP (1) | EP3400013A4 (https=) |
| JP (3) | JP6974348B2 (https=) |
| KR (1) | KR20180127966A (https=) |
| CN (4) | CN113817059B (https=) |
| AU (1) | AU2017206089B2 (https=) |
| IL (1) | IL260474B (https=) |
| WO (1) | WO2017120557A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021524576A (ja) * | 2018-05-16 | 2021-09-13 | アーベル リミテッドＡｒｂｅｌｅ Ｌｉｍｉｔｅｄ | がんの診断及び治療のための組成物及び方法 |
| US20210115152A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| JP7812549B2 (ja) * | 2019-02-21 | 2026-02-10 | アーベル リミテッド | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| US20230340119A1 (en) * | 2019-12-05 | 2023-10-26 | Arbele Corp | Composition of triax antibodies and method of making and using thereof |
| JP2024523033A (ja) * | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| EP4413366A4 (en) * | 2021-10-08 | 2025-09-10 | Tiberias Tech Hk Limited | TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17 |
| CA3240301A1 (en) * | 2021-12-07 | 2023-06-15 | Dennis Slamon | Cdh17 antibodies and methods of treating cancer |
| CN113999308B (zh) * | 2021-12-30 | 2022-03-11 | 深圳市人民医院 | 靶向钙粘蛋白17的纳米抗体及其应用 |
| AU2023377353A1 (en) | 2022-11-11 | 2025-05-22 | Ospedale San Raffaele S.R.L. | Cdh17 car |
| CN120712286A (zh) * | 2023-02-23 | 2025-09-26 | 翰森生物有限责任公司 | 抗体、抗原结合片段和使用方法 |
| WO2024220437A2 (en) * | 2023-04-17 | 2024-10-24 | Arbele Limited | Compositions and methods for determining the effects of t cell engager |
| WO2024240227A1 (en) * | 2023-05-24 | 2024-11-28 | Multitude Therapeutics Inc. | Antibodies and antibody-drug conjugates thereof |
| AU2024347590A1 (en) * | 2023-09-22 | 2026-04-09 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibodies and uses thereof |
| CN120137019A (zh) * | 2023-12-11 | 2025-06-13 | 东莞市朋志生物科技有限公司 | 一种抗糖化血红蛋白HbA1c的抗体及其应用 |
| CN120230211A (zh) * | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| CN120988128A (zh) * | 2024-05-20 | 2025-11-21 | 杭州中美华东制药有限公司 | 抗cdh17抗体、其抗体药物偶联物及其用途 |
| WO2025242099A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体偶联药物及其用途 |
| WO2025242100A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体及其用途 |
| WO2025252211A1 (zh) * | 2024-06-07 | 2025-12-11 | 映恩生物制药（苏州）有限公司 | 抗人cdh17抗体 |
| WO2026015644A1 (en) * | 2024-07-10 | 2026-01-15 | The Trustees Of The University Of Pennsylvania | Cadherin-17 targeting antigen biding polypeptides, chimeric antigen receptors, car-t cells and methods of treating cadherin-17 positive cancers |
| US20260078179A1 (en) * | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
| WO2026046327A1 (en) * | 2024-08-29 | 2026-03-05 | Utc Therapeutics (Shanghai) Co., Ltd. | Cdh17 targetting antibodies, chimeric antigen receptors, and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| CN102936287B (zh) | 2008-02-08 | 2015-09-09 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| US8435749B2 (en) * | 2008-06-30 | 2013-05-07 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies labeled with radioisotope label and uses thereof |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| DK2421898T3 (en) * | 2009-04-20 | 2016-05-30 | Oxford Biotherapeutics Ltd | Cadherin-17 SPECIFIC ANTIBODIES |
| LT2535358T (lt) * | 2010-02-10 | 2018-03-26 | Fujifilm Ri Pharma Co., Ltd. | Radioaktyvus metalu žymėtas anti-kadherino antikūnas |
| RS57215B1 (sr) * | 2010-07-15 | 2018-07-31 | Adheron Therapeutics Inc | Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima |
| US20130259878A1 (en) * | 2010-10-20 | 2013-10-03 | Oxford Biotherapeutics Ltd | Antibodies |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| EP2948478B1 (en) * | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
-
2017
- 2017-01-07 CN CN202111238201.1A patent/CN113817059B/zh active Active
- 2017-01-07 CN CN201780005758.6A patent/CN108778327B/zh active Active
- 2017-01-07 US US16/068,665 patent/US11207419B2/en active Active
- 2017-01-07 KR KR1020187023033A patent/KR20180127966A/ko not_active Ceased
- 2017-01-07 CN CN202111238599.9A patent/CN113912725B/zh active Active
- 2017-01-07 AU AU2017206089A patent/AU2017206089B2/en active Active
- 2017-01-07 EP EP17736491.6A patent/EP3400013A4/en active Pending
- 2017-01-07 WO PCT/US2017/012648 patent/WO2017120557A1/en not_active Ceased
- 2017-01-07 CN CN202111238485.4A patent/CN113817060B/zh active Active
- 2017-01-07 JP JP2018554645A patent/JP6974348B2/ja active Active
-
2018
- 2018-07-08 IL IL260474A patent/IL260474B/en active IP Right Grant
-
2021
- 2021-11-04 JP JP2021179905A patent/JP7275232B2/ja active Active
-
2023
- 2023-05-02 JP JP2023075948A patent/JP7482287B2/ja active Active